BBIO Stock Forecast: BridgeBio Pharma, Inc. Price Predictions for 2026-2027
The 22 Wall Street analysts covering BridgeBio Pharma, Inc. hold a median 12-month price target of $108 — +41.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 80 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores BridgeBio Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (95): The share price has been relatively steady.
Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BBIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +41.3% from it.
Of the 20 most recent actions, 13 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Morgan Stanley | Maintains | Overweight | $88 → $91 |
| 2 Nov 2026 | Canaccord Genuity | Maintains | Buy | $106 → $108 |
| 30 Oct 2026 | Morgan Stanley | Maintains | Overweight | $87 → $88 |
| 30 Oct 2026 | TD Cowen | Maintains | Buy | $110 → $100 |
| 21 Oct 2026 | Morgan Stanley | Maintains | Overweight | $97 → $87 |
| 19 Oct 2026 | Citigroup | Maintains | Neutral | $94 → $91 |
| 19 Oct 2026 | Piper Sandler | Maintains | Overweight | $115 → $120 |
| 15 Oct 2026 | UBS | Assumes | Buy | $82 → $92 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $157 → $156 |
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 1 Sept 2026 | Mizuho | Maintains | Outperform | $96 → $110 |
| 12 Aug 2026 | Canaccord Genuity | Maintains | Buy | $104 → $106 |
| 12 Aug 2026 | JP Morgan | Maintains | Overweight | $100 → $111 |
| 12 Aug 2026 | Truist Securities | Maintains | Buy | $102 → $107 |
| 11 Aug 2026 | B of A Securities | Maintains | Buy | $101 → $104 |
| 11 Aug 2026 | Morgan Stanley | Maintains | Overweight | $98 → $97 |
| 11 Aug 2026 | Piper Sandler | Maintains | Overweight | $111 → $115 |
| 11 Aug 2026 | TD Cowen | Maintains | Buy | $95 → $110 |
| 11 Aug 2026 | Wells Fargo | Maintains | Overweight | $98 → $102 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BBIO.
This page is one stock. Monday covers all of them.
BBIO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BBIO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, BridgeBio Pharma, Inc. returned +17.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BBIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 15.7×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 9% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 93.8%
- Operating margin
- −37.3%
- Net margin
- —
Higher than 98% of US stocks
Higher than 19% of US stocks
- Return on equity
- —
- Return on assets
- −14.0%
- Dividend yield
- —
Higher than 23% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BridgeBio Pharma, Inc. has a market value of $14.8B and an enterprise value of $17.6B.
Revenue in the twelve months to 30 June 2026: $713.1M. The latest quarter grew 120.4% year on year.
Net income over the same four quarters: −$702.0M, a −98.5% net margin.
Diluted earnings per share, trailing twelve months: −$3.57.
Free cash flow in the twelve months to 30 June 2026: −$437.8M.
BridgeBio Pharma, Inc. spent $228.8M on share buybacks in the twelve months to 30 June 2026.
BridgeBio Pharma, Inc. employs 1,081 people — $660K of revenue per employee.
Data provided by Twelve Data
BBIO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BBIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own BridgeBio Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BBIO
What is the BBIO stock price forecast for 2026-2027?
The 22 Wall Street analysts covering BridgeBio Pharma, Inc. have a median 12-month price target of $108, with estimates ranging from $80 to $156. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BBIO stock a buy right now?
Of the 22 analysts covering BridgeBio Pharma, Inc., 19 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BridgeBio Pharma, Inc. 80 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BBIO?
As at 21 Nov 2026, BridgeBio Pharma, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (95 of 100).
Will BBIO stock go up?
No one can know that. What the data says: the median 12-month target from 22 analysts implies +41.3% from the last close, and Ticker Nerd's factor model ranks BridgeBio Pharma, Inc. 80 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BBIO stock forecast for 2030?
No analyst covering BridgeBio Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $156 over the next 12 months.
How has BBIO stock performed over the past year?
BridgeBio Pharma, Inc. returned +17.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does BridgeBio Pharma, Inc. do?
BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions. BridgeBio Pharma Inc. discovers, develops, tests, and delivers therapies aimed at patients with rare and inherited diseases, with programs spanning cardiology, endocrinology, muscle disease, gene therapy, and selected oncology.
About BridgeBio Pharma, Inc.
BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions. BridgeBio Pharma Inc. discovers, develops, tests, and delivers therapies aimed at patients with rare and inherited diseases, with programs spanning cardiology, endocrinology, muscle disease, gene therapy, and selected oncology. The company’s current portfolio includes approved medicines such as Attruby for transthyretin amyloid cardiomyopathy and Nulibry for a rare metabolic disorder, alongside a pipeline of investigational treatments for additional genetic disorders. BridgeBio Pharma Inc. works with academic and industry partners to advance precision medicines and bring targeted treatment options to underserved patient groups. Headquartered in Palo Alto, California, BridgeBio Pharma Inc. plays a significant role in the genetic-disease biopharmaceutical market through its mix of commercial products and late-stage development programs.
CEO Dr. Neil Kumar Ph.D. · 1,081 employees · United States · https://bridgebio.com